Thank you very much. My name is Märta Lewander Xu, and today I will present the company Gasporox that I built the last 15 years together with my team. What we work on is getting a safer world through improving the packaging. What we do is that we inspect packages. With packages, I often mean vials, I would say. Our core application is parenterals in an injectable dosage of some kind, vials, prefilled syringe, cartridges, ampules, IV bags, et cetera, you name it. How do we do this? We use a laser-based technology. We have a simple sensor that you can place directly online. We also have instruments. We were founded already in 2004 of a research group that I was part of. In 2011, we started our commercial journey. We got listed in 2016. In 2020, we started our commercial scale-up.
Today, I would say we have around 1,000 installations worldwide. I would dare to say that most of you have gotten injection, like a vaccine, that has been inspected by our technology. Something you just take for granted, that what you get injected into your body is safe, active, is something we control every day out on our factories. What we are doing now is that we are taking next step and not being just a technology provider, but also supplying the full value chain and also having a new exciting technology moving from parenteral drugs to oral solids. We are moving into a tablet world, which is very exciting. Let's start with why is headspace and package integrity important? I think if you get an injection, you want it to be safe, that it is sterile, no bacteria gets in.
If you get a cancer treatment, we have heard of amazing drugs today in molecules and proteins and treatments, but many of them are oxygen sensitive. If they experience oxygen in their package, they are dead when they come to their patient. This is something we inspect, that okay, are they packaged with nitrogen? It needs to be shown that it is yes, there is no oxygen inside degrading your product. We are mainly in the sterile parenteral segment, but we also have food and beverage applications. We are often part of a product release when you have produced a batch that they check. It is a very regulated market where more or less if you develop, produce, you have to do the test that we supply more or less, in your formulation development and also in your batch release.
What we use is a laser-based technology. We shine a laser light straight through a container. It goes quickly. We go up to 600 vials per minute, so in the speed of a production line. This is quite revolutionary that today you often use destructive testing. You have needles approaching to suck out the gas, analyzing it with a mass spectrometry or some electrochemical approach. Many people are aware of the blue dye test where you put all your packages in a bowl of blue dye and then you check, did they become blue? That is the way to check if some bacteria came in. What we can do is that we, by just shining laser lights right through it, we can say, "Yes, it is the right gas inside. Yes, there has not been any leakage down to one micron," for example.
This is really important for the pharmaceutical industry to get out safe drugs. We have a technology as our base, but it is a scalable platform. I have talked a lot on parenterals, and that is our core application, vials, ampules. We also have applications in food and beverages where you have modified atmosphere to get an extended shelf life. We are also now moving into oral solid dose, where we, by shining laser light through a tablet, we can present how much gas is it inside. This gas connects to the dissolution of the tablet. There is a clear link between porosity and dissolution.
Instead of having to do these water bath methods where you check how much was dissolved into the water, by shining the laser light through the tablet, we can say, "This is the porosity and this is the dissolution." This is a very novel technology. I would say our headspace analysis, we have been out now for over 10 years, but this tablet inspection is totally new and we are launching the first CE marked product by the end of this year. What we offer is a technology, but we also have everything from a lab to inline solution. Our entry point is often what we call Lab Luna. That is our commercial entry point. You can test your packages, tablets, et cetera, inside our in-house lab with our experts and you will get a report.
It can be a feasibility study, but it can also be a way to support in getting your approvals from EMA. We recently made a transport study for a customer showing that the product was not affected by being transported by ocean or by air, something EMA demanded. We have a lot of expertise in guiding customers to get the right testing done. By having this, we have bench top units, so you can have either in a lab or by your production. We have inline sensors that you can place directly on your production line, testing 100%. Recent now, since a year ago, we also have more complete solution for inline, a line that we call LineArch. We had our first installation here in Europe, this year of it.
That is very exciting for us to go from a technology provider to being more a full solution turnkey provider. I talked a lot about the pharma and parenterals, and that is our initial focus market. We have a very clear application there. We are part of the recommended methods in the United States Pharmacopeia in the EU GMP Annex 1. They are moving over what is called deterministic testing instead of probabilistic testing, et cetera. We are all in line in this. There is a willingness to pay, because they can get blocked. We have customers getting blocked for delivering their products until you have solved the leakage solution problem. I would say, we estimate that there is up to 10,000 pharmaceutical lines that need our equipment and around 1,000 labs.
While if you look in the food and beverage, they are a factor 10 more, around 100,000 lines of beverage and 100,000 of food. We see there are more installation possibilities within food and beverage, but we have had a focus on parenterals as a first step. We are moving more and more, I would say, in food as well, and having applications from Parma ham to peanut butter. Next time you eat something, you should also be aware that it is often packaged not in air, but in modified atmosphere. With beverage, I think all of you have had some champagne or Coke. That is also, in some sense, a gas, in some type of gas, and this is also applications that we support.
Very exciting now is the oral solid dose, where we do then moving over to tablets, actually adding a quite huge market capability to our offering. Looking a bit on our numbers, we have been growing for the 10 years and now plateaued around SEK 30 million in our turnover. We produce in-house in Lund. We deliver, we have an international sales team originating from Switzerland. We are a team of 22, but quite a complete team in this small package. We have a positive EBITDA, which is where we have put the focus as well. We are listed on Nasdaq First North Growth Market, but we also have stable, large owners. You heard of Gobia Enterprises here, part of the panel, for example, also my chairman. We have had a first good half year here with growth. We are also still doing heavy investments.
This is one that we did two years ago. In 2024, we said, "Okay, things are running, but we also see more potential. Can you also add the tablet area?" Then I said, "I can do, but then I will need a bit more money to run this part as well." We decided to take in a little bit money in January 2024 and had some clear targets. To get the CE mark product for the tablet, check on this one. Getting a machine and having this one installed. We had first installed here in July. Also having the Lab Luna also offering, and having a more complete solution in vials, because here we really see that we have got into the market and got a first grasp, you can say. This is progressing really well, and it is really exciting.
Some are a bit behind and some are ahead, which is natural in development. What makes Gasporox a unique case? I would say we are really in the interception between a tech company and a life science company, and this is where really the magic happens. That is like you de-risk in some sense. We are not just one out of 10 that will work. We work. We have 1,000 installations. At the same time, there is a business to be built, and that is what we are working on right now. We have a commercial momentum. We have new, exciting products coming out on the market. It is a scalable business model. We have an annual revenue from each installation we do, that we get more also when we work directly to end users and not integrators.
We have multiple growth vectors in pharma and in food, and also now solids. We have an amazing team, I would say, both owner, board, myself. I celebrated 15 years in the company, and it's really, how to say, a blessing to be able to build up a company where you really feel that you can make a difference for many people, but also providing a technology that is really useful for the industry. With that, I want to open for questions.
Thank you, Märta. Right. Do we have any questions in the room?
I've followed you for a distance for many years. I would have thought that the industry would save money by using your technology. Why is the adoption so slow?
I think the answer is in this room. We also see that it takes time in life science. There are money there, but it's a slow-moving industry. To get a new technology, you need to prove, and prove, improve. I would say that is part of why it's not going as fast as any CEO wants.
Are there any regulatory demands that you can see in the shadow, so to speak?
Definitely. I would say that everything that you need to do a stability study, I talked about this transport study, you need to do your packaging study, you need to do your process study, you need to do your batch release. There are quite many studies. We have been very focused on when you produce a drug. What I am targeting now, many people talk about the aftermarket, but I want the 20 years pre-market when the drug is being developed, because there is a lot of testing occurring at that phase.
Yeah, but my point was that the industry must use your or some other technology, and if not, they cannot continue with their production.
Yeah, and I would say that this, yes and no. There is a set of technologies that is recommended, but at the same time, you have all drugs approved with blue dye testing, and then they can still use it. It takes time to move in new technology, because if you have gotten approval with an old testing, you are allowed to still produce with that one. But new drugs are not allowed to use this. It should be phased out, really. I would say that we are mentioned as the recommended method both in USP and in the Annex 1. But it is a slow market to get it in.
We have a question over there.
Yes. Are there thresholds in regards of the pharmaceutical companies in order to have adapted their standard operating procedures for production before they can include your technology in their business?
If it's thresholds, do you mean if it's like a hurdle to get through? I would say, and it connects a little bit to your last question, the regulatory today demands that you do testing, but they don't demand 100% testing. So it's enough that you do spot checking with the instruments. I'm trying to get the full industry to understand you should demand 100% testing. But the capability has not been there before, so then the regulatory has not said it. But I would say that the hurdle is to show the regulatory demands, and we even have training for the industry, like how do you fulfill the regulatory to have different technology.
Yeah. But my question is if there are hurdles for you in order to secure deals with pharma companies, for instance, hurdles in regards of their standard operating procedures for production in order to use your product.
No, I wouldn't say that. We are used to working with the quality teams and getting it into their quality systems, et cetera, and our software is compliant with the 21 CFR Part 11, et cetera. So we are used to the environment, and it is a plug-and-play to get in, but when you move over to a method, you need to validate it, you need to do the method development. And this is also something we are now even more helping them with having our own lab, so we can go in and do the method development for them as an offering. And so that's why we see that we have broadened our offering to them, trying to also lower this, how to say, a competence hurdle that maybe you are referring to.
Thank you so much, Märta.
Thank you.